“`html
In a recent Supreme Court argument involving Hikma Pharmaceuticals USA v Amarin Pharma, the bench expressed skepticism towards litigation aimed at holding a manufacturer liable for pharmacists’ actions regarding prescriptions. The case centers around Hikma, a manufacturer of generic pharmaceuticals, and its relation to Amarin Pharma, the patent holder of Vascepa, a medication aimed at reducing heart disease. The dispute arises when Hikma’s product is dispensed for uses that infringe on Amarin’s patents.
Central to yesterday’s arguments, the justices questioned the merits of imposing liability on Hikma for the decisions made by pharmacists, recalling an earlier decision in the Cox Communications case, where liability for third-party actions was already doubted.
The Federal Circuit Court previously upheld a complaint against Hikma, attributing potential inducement to three statements: product labels, investor-targeted press releases, and website declarations. These are seen as inciting unauthorized use of the product. However, the justices found the evidence presented not convincing enough to meet the statute’s “active inducement” requirement under the Patent Act.
The concern around labels, largely dictated by the FDA, saw skepticism from Justices Ketanji Brown Jackson and Elena Kagan on holding generics culpable. Likewise, press releases, directed at investors, did not persuade the justices of any intent to influence pharmacists, with Justice Jackson being particularly vocal about this. The website, seen as merely identifying Hikma’s product as a generic equivalent, was not deemed incendiary, especially since it featured a disclaimer that some, led by Justice Neil Gorsuch, considered pivotal.
Interestingly, the justices, notably Justice Sonia Sotomayor, questioned the relevance of the Supreme Court’s involvement in this fact-specific case, echoing concerns from Justice Amy Coney Barrett about the case’s factual nature. Contrarily, Justice Brett Kavanaugh, who favored hearing this case, underscored potential market-wide implications of the lower court’s decision.
The court appears likely to issue a concise, unanimous opinion, focusing on the insufficient probative value of the evidence for demonstrating “active” inducement rather than passive acquiescence, aligning with the critiques voiced during the proceedings. For further details, you can access the complete article via SCOTUSblog.
“`